95 related articles for article (PubMed ID: 16945954)
1. Kinome-wide functional screen identifies role of PLK1 in hormone-independent, ER-positive breast cancer.
Bhola NE; Jansen VM; Bafna S; Giltnane JM; Balko JM; Estrada MV; Meszoely I; Mayer I; Abramson V; Ye F; Sanders M; Dugger TC; Allen EV; Arteaga CL
Cancer Res; 2015 Jan; 75(2):405-14. PubMed ID: 25480943
[TBL] [Abstract][Full Text] [Related]
2. Targeted PLK1 suppression through RNA interference mediated by high-fidelity Cas13d mitigates osteosarcoma progression via TGF-β/Smad3 signalling.
Yuan Y; Cao D; Zhang A; Liu Z; Deng Z; Zhang S
J Cell Mol Med; 2024 May; 28(10):e18400. PubMed ID: 38780513
[TBL] [Abstract][Full Text] [Related]
3. Gene Silencing via RNA Interference in Cryptococcus.
Bose I
Methods Mol Biol; 2024; 2775():91-106. PubMed ID: 38758313
[TBL] [Abstract][Full Text] [Related]
4. Inducible, reversible, and stable RNA interference in mammalian cells.
Gupta S; Schoer RA; Egan JE; Hannon GJ; Mittal V
Proc Natl Acad Sci U S A; 2004 Feb; 101(7):1927-32. PubMed ID: 14762164
[TBL] [Abstract][Full Text] [Related]
5. PLK1 has tumor-suppressive potential in APC-truncated colon cancer cells.
Raab M; Sanhaji M; Matthess Y; Hörlin A; Lorenz I; Dötsch C; Habbe N; Waidmann O; Kurunci-Csacsko E; Firestein R; Becker S; Strebhardt K
Nat Commun; 2018 Mar; 9(1):1106. PubMed ID: 29549256
[TBL] [Abstract][Full Text] [Related]
6. Embedding siRNA sequences targeting apolipoprotein B100 in shRNA and miRNA scaffolds results in differential processing and in vivo efficacy.
Maczuga P; Lubelski J; van Logtenstein R; Borel F; Blits B; Fakkert E; Costessi A; Butler D; van Deventer S; Petry H; Koornneef A; Konstantinova P
Mol Ther; 2013 Jan; 21(1):217-27. PubMed ID: 23089734
[TBL] [Abstract][Full Text] [Related]
7. Conditional gene manipulation: Cre-ating a new biological era.
Zhang J; Zhao J; Jiang WJ; Shan XW; Yang XM; Gao JG
J Zhejiang Univ Sci B; 2012 Jul; 13(7):511-24. PubMed ID: 22761243
[TBL] [Abstract][Full Text] [Related]
8. Cdk1/cyclin B1 controls Fas-mediated apoptosis by regulating caspase-8 activity.
Matthess Y; Raab M; Sanhaji M; Lavrik IN; Strebhardt K
Mol Cell Biol; 2010 Dec; 30(24):5726-40. PubMed ID: 20937773
[TBL] [Abstract][Full Text] [Related]
9. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy.
Strebhardt K
Nat Rev Drug Discov; 2010 Aug; 9(8):643-60. PubMed ID: 20671765
[TBL] [Abstract][Full Text] [Related]
10. RNAi reduces expression and intracellular retention of mutant cartilage oligomeric matrix protein.
Posey KL; Liu P; Wang HR; Veerisetty AC; Alcorn JL; Hecht JT
PLoS One; 2010 Apr; 5(4):e10302. PubMed ID: 20421976
[TBL] [Abstract][Full Text] [Related]
11. In vivo gene regulation using tetracycline-regulatable systems.
Stieger K; Belbellaa B; Le Guiner C; Moullier P; Rolling F
Adv Drug Deliv Rev; 2009 Jul; 61(7-8):527-41. PubMed ID: 19394373
[TBL] [Abstract][Full Text] [Related]
12. A novel short hairpin RNA (shRNA) expression system promotes Sox9-dependent gene silencing.
Gilbert JR; Adams CS; Shapiro IM; Hickok NJ
Plasmid; 2009 Jul; 62(1):50-5. PubMed ID: 19389425
[TBL] [Abstract][Full Text] [Related]
13. RNA interference: from basic research to therapeutic applications.
Kurreck J
Angew Chem Int Ed Engl; 2009; 48(8):1378-98. PubMed ID: 19153977
[TBL] [Abstract][Full Text] [Related]
14. Contemporary approaches for modifying the mouse genome.
Adams DJ; van der Weyden L
Physiol Genomics; 2008 Aug; 34(3):225-38. PubMed ID: 18559964
[TBL] [Abstract][Full Text] [Related]
15. Development and implementation of a miniaturized high-throughput time-resolved fluorescence energy transfer assay to identify small molecule inhibitors of polo-like kinase 1.
Sharlow ER; Leimgruber S; Shun TY; Lazo JS
Assay Drug Dev Technol; 2007 Dec; 5(6):723-35. PubMed ID: 18181689
[TBL] [Abstract][Full Text] [Related]
16. Comparison of RNAi efficiency mediated by tetracycline-responsive H1 and U6 promoter variants in mammalian cell lines.
Henriksen JR; Løkke C; Hammerø M; Geerts D; Versteeg R; Flaegstad T; Einvik C
Nucleic Acids Res; 2007; 35(9):e67. PubMed ID: 17426119
[TBL] [Abstract][Full Text] [Related]
17. Reversible gene knockdown in mice using a tight, inducible shRNA expression system.
Seibler J; Kleinridders A; Küter-Luks B; Niehaves S; Brüning JC; Schwenk F
Nucleic Acids Res; 2007; 35(7):e54. PubMed ID: 17376804
[TBL] [Abstract][Full Text] [Related]
18. Tumor inhibition by genomically integrated inducible RNAi-cassettes.
Kappel S; Matthess Y; Zimmer B; Kaufmann M; Strebhardt K
Nucleic Acids Res; 2006; 34(16):4527-36. PubMed ID: 16945954
[TBL] [Abstract][Full Text] [Related]
19. Conditional inhibition of cancer cell proliferation by tetracycline-responsive, H1 promoter-driven silencing of PLK1.
Matthess Y; Kappel S; Spänkuch B; Zimmer B; Kaufmann M; Strebhardt K
Oncogene; 2005 Apr; 24(18):2973-80. PubMed ID: 15735719
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
